Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Eli Lilly and Company   /   Eli Lilly and Company (LLY)

Aandeel Eli Lilly & Co NYS:LLY.N, US5324571083

Vertraagde koers (usd) Verschil Volume
774,415   -8,755   (-1,12%) Dagrange 771,000 - 777,985 447.900   Gem. (3M) 3,7M

Eli Lilly and Company (LLY)

Volgen
33 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  2. forum rang 5 Lieutenant Price 16 oktober 2024 14:10
    quote:

    nb schreef op 14 oktober 2024 19:48:

    Yep, ben er vorige week toch weer ingestapt. Novo durf ik ( nog) niet.
    Denk dat viking ook best goede kansen maakt met een pil.
    Welkom terug aan boord! :-)

    Novo Nordisk had ik onlangs op 785 DK gekocht, denk dat het op den duur wel weer zal herstellen richting 900 regionen.
  3. forum rang 5 Lieutenant Price 22 oktober 2024 16:22
    Lilly sues online vendors, medical spa over copycat weight-loss drugs

    "(Reuters) - Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.

    The new lawsuits, which name Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine of Nevada, are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month.

    Lilly said these lawsuits were not in any way contingent on tirzepatide coming off of that list and could have been filed regardless of whether supply issues had been resolved.

    Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Medical spa Genesis sells and administers compounded versions of the drug, according to the lawsuits.

    Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes.

    The lawsuits were filed in federal and state courts in Indiana, Texas and Washington, accusing each defendant of false advertising and promotion. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit.

    "Lilly is bringing these actions to protect American consumers from direct patient safety risks," said a spokesperson for the drugmaker, adding that the defendants were making false claims about efficacy or safety, and misleading consumers about the clinical data used to back them.

    The Indianapolis-based drugmaker has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro.

    In its most recent filings, Lilly said MangoRx was selling an oral version of tirzepatide branded as Trim, despite the lack of any study showing that formulation to be safe and effective. The FDA to date has only approved tirzepatide as an injectable drug.

    After Lilly sent Pivotal Peptides a cease and desist letter, the vendor changed its website to say it was under maintenance and altered its operations to sell via email, social media, and word of mouth, according to the drugmaker's lawsuit.

    Lilly said Genesis was claiming to sell compounded tirzepatide with vitamin B12, and that such combinations are "untested, unproven, and expose consumers to an unjustifiable risk of harm."

    Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages."
    finance.yahoo.com/news/lilly-sues-onl...
  9. forum rang 5 Lieutenant Price 26 november 2024 14:56
    Biden to propose expanded Medicare, Medicaid coverage of obesity drugs, official says


    "WASHINGTON (Reuters) -U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid, which could cut out-of-pocket expenses for some by as much as 95%.

    This would enable more Americans to afford new weight loss medications that can help prevent type 2 diabetes and lower the risk of death and heart attacks by up to 20%, but cost as much as $1,000 a month without insurance coverage.

    Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.

    A new proposed regulation, to be published by the Department of Health and Human Services on Tuesday, would require Medicare to cover these drugs as a treatment for obesity, expanding access for an estimated 3.4 million Americans with Medicare.

    "Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees," the White House said in a statement.

    It would also ensure access to the medications for approximately 4 million adult Medicaid enrollees, it said."

    app.piqsuite.com/reuters/biden-to-pro...

    Eli Lilly and Company (LLY) 787.00 +32.00 (+4.24%) Pre-Market: 8:55 AM EST
  13. forum rang 5 Lieutenant Price 20 december 2024 12:21
    Eli Lilly and Company (LLY) 835.00 +77.46 (+10.23%) Pre-Market: 6:19:44 AM EST

    Novo Nordisk A/S (NOVO-B.CO) 571.20 -172.00 (-23.14%)

    Novo Nordisk shares tumble as weight-loss drug trial data disappoints

    "Novo Nordisk, one of Europe’s largest companies, lost more than a quarter of its value on Friday after its latest obesity drug missed the drugmaker’s goal for an average of 25 per cent weight loss.

    CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of rival Eli Lilly’s Mounjaro.

    Martin Holst Lange, executive vice-president for development at Novo Nordisk, said that only 57 per cent of patients had received the highest dose of the drug. “We are encouraged by the weight-loss profile of CagriSema,” he said.

    The company’s shares were down as much as 27 per cent in mid-morning trading in Denmark.

    Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.

    Novo Nordisk had hoped its “next generation” weight-loss drug could lead the field, after its shares had struggled to keep pace with Eli Lilly and it suffered a setback from disappointing results for an experimental weight-loss pill in September.

    “CagriSema is really important for us,” chief executive Lars Fruergaard Jørgensen told the Financial Times in November. “It’s a next-generation product and it has the potential to be best in class.”

    Patients receiving Mounjaro lost an average of 22.5 per cent of their weight in phase 3 trials when taken as part of a regime of improved diet and exercise. Those on Wegovy, also made by Novo Nordisk, lost an average of about 15 per cent in similar conditions.

    About 40 per cent of patients in the CagriSema trial achieved 25 per cent weight loss over the 68 weeks.

    CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, another hormone that makes people feel fuller for longer.

    The trial of 3,417 people taking the weekly injection found that the most common side effects were gastrointestinal, the vast majority of which were mild and moderate and diminished over time."

    www.ft.com/content/a91c249f-61f4-4613...
33 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Eli Lilly & Co Nieuws

  1. Eli Lilly verhoogt dividend en gaat opnieuw eigen aandelen inkopen
  2. Angst voor handelsoorlog drukt AEX in het rood, messen geslepen voor PCE-inflatie en Fed-notulen
  3. Eli Lilly stelt teleur
  4. Eli Lilly verhoogt outlook weer
  5. Het ziet er nog niet goed uit voorbeurs, maar gaat SBM Offshore stunten?
  6. Alzheimer-medicijn van Eli Lilly wellicht later dit jaar op de markt
  7. Eli Lilly verhoogt outlook
  8. Eli Lilly krijgt impuls door succes obesitasmedicijn
  9. Flinke winstwaarschuwing Eli Lilly
  10. Aandelen voedingsmiddelenconcerns onder druk door populariteit afslankmiddelen